Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

CKD-510 is under development for the treatment of Charcot-Marie-Tooth disease and atrial fibrillation. It is administered through oral route.The drug candidate is a new chemical entity targeting ...

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.

Selenium sulfide is under clinical development by Azura Ophthalmics and currently in Phase II for Unspecified Ophthalmological Disorders.

NVK-004 is under clinical development by Nevakar Injectables and currently in Pre-Registration for Unspecified Cardiovascular Disorders.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

Dactolisib tosylate is under clinical development by Adicet Bio and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

VTP-500 is under clinical development by Barinthus Biotherapeutics and currently in Phase I for Middle East Respiratory Syndrome (MERS).

CT-7439 is under development for the treatment of solid tumors including breast cancer, ovarian cancer and Ewing's Sarcoma. It acts by targeting cyclin dependent kinase 12 and 13 (CDK12 and 13). It is ...

TAS-0728 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Endometrial Cancer.

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Solid Tumor.